Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
ReST Therapeutics
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05921929CT.gov First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neurodegenerative Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluoroethylnormemantine (this asset) | ReST Therapeutics | P1 | CC · 43 |
| Atorvastatin | Monash University | P4 | BB |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | BB |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | BB |
| Pimavanserin | Vanderbilt University Medical Center | P4 | BB |
| Levodopa | Merck Sharp & Dohme LLC | P2 | B |
| Donanemab | Eli Lilly and Company | P3 | B |
| Dexasone | Eli Lilly and Company | P3 | B |
| Nexiguran Ziclumeran | Intellia Therapeutics | P3 | B |
+33 more in the Neurodegenerative Disease cohort
Other indications for Fluoroethylnormemantine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Post-Traumatic Stress Disorder | — | P1 | CC · 41 |
| Brain Disorder | — | P1 | CC · 41 |
| Alzheimer Disease | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluoroethylnormemantine in Neurodegenerative Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluoroethylnormemantine-neurodegenerative-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →